Tanya D Tran, OD
Optometry · Milpitas
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Tran’s office at (408) 885-5000 to ask if they take your plan before you enroll.
Medicaid work
$169,058 in 2024
Medicaid paid $169,058 for 1,062 billed services this clinician did in 2024, up to 49 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 319 | $161,923 |
| Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 12 | $5,416 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 344 | $1,719 |
| Pain severity quantified; no pain present (COA) (ONC) | 33 | $0 |
| Medication list documented in medical record (COA) | 276 | $0 |
| Aspirin or clopidogrel prescribed or currently being taken (CAD) | 15 | $0 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 45 | $0 |
| Clinician prescribed angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy | 18 | $0 |
| 2024 | 1,062 | 8 | 49 | $169,058 |
| 2023 | 978 | 6 | 51 | $160,810 |
| 2022 | 1,266 | 9 | 50 | $146,576 |
| 2021 | 1,085 | 11 | 50 | $168,177 |
| 2020 | 630 | 3 | 33 | $90,647 |
| 2019 | 696 | 4 | 47 | $103,374 |
| 2018 | 675 | 4 | 41 | $114,744 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 309 | $152,743 |
| Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 13 | $5,868 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 571 | $2,199 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 40 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 16 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 29 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 302 | $145,519 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 547 | $1,057 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 67 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 52 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 13 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 63 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 147 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 31 | $0 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 44 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 354 | $168,132 |
| Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | 24 | $45 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 54 | $0 |
| Most recent hemoglobin A1c (HbA1c) level greater than or equal to 7.0% and less than 8.0% (DM) | 12 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 45 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 12 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 68 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 139 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 14 | $0 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 31 | $0 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 332 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 281 | $88,080 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 324 | $2,567 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 25 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 324 | $99,817 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 306 | $3,557 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 25 | $0 |
| Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 41 | $0 |
2018
| Clinic visit/encounter, all-inclusive | 370 | $112,387 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 220 | $2,157 |
| Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 61 | $200 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 24 | $0 |
Drugs they prescribed that Part D paid
$5,929
Pharmacies billed $5,929 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 57) in 2024. At or below the middle of the specialty; the typical optometry clinician is at 0%.
50 generic and fewer than 11 brand-name prescriptions · $5,929 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Flurbiprofen | 18 | $585 | $32 |
| Latanoprost | 13 | $86 | $7 |
Year by year
| 2024 | 57 | 20 | 0% (0) | None | $5,929 |
| 2023 | 60 | 20 | 0% (0) | 32% | $11,644 |
| 2022 | 95 | 25 | 0% (0) | 25% | $14,594 |
| 2021 | 118 | 28 | 0% (0) | 15% | $12,971 |
| 2020 | 102 | 23 | 0% (0) | 21% | $13,070 |
| 2019 | 54 | 20 | 0% (0) | None | $4,516 |
| 2018 | 65 | 21 | 0% (0) | 55% | $4,410 |
| 2017 | 41 | 16 | 0% (0) | 54% | $3,185 |
| 2016 | 33 | 16 | 0% (0) | None | $1,179 |
| 2015 | 61 | 24 | 0% (0) | 56% | $8,121 |
| 2014 | 78 | 27 | 0% (0) | 38% | $4,707 |
| 2013 | 64 | 32 | 0% (0) | 52% | $4,440 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Restasis | 12 | $8,368 | $697 |
| Flurbiprofen | 15 | $477 | $32 |
| Olopatadine | 12 | $220 | $18 |
2022: 3 drugs
| Restasis | 16 | $10,081 | $630 |
| Flurbiprofen | 45 | $1,479 | $33 |
| Azelastine | 12 | $972 | $81 |
2021: 3 drugs
| Restasis | 13 | $8,094 | $623 |
| Olopatadine | 29 | $2,698 | $93 |
| Flurbiprofen | 46 | $1,530 | $33 |
2020: 3 drugs
| Restasis | 14 | $9,396 | $671 |
| Flurbiprofen | 43 | $1,469 | $34 |
| Olopatadine | 21 | $500 | $24 |
2019: 2 drugs
| Olopatadine | 17 | $1,095 | $64 |
| Flurbiprofen | 24 | $756 | $31 |
2018: 2 drugs
| Olopatadine | 18 | $1,553 | $86 |
| Flurbiprofen | 19 | $134 | $7 |
2017: 2 drugs
| Pataday | 16 | $2,554 | $160 |
| Flurbiprofen | 13 | $85 | $7 |
2015: 1 drug
| Patanol | 31 | $7,273 | $235 |
2014: 2 drugs
| Patanol | 22 | $3,330 | $151 |
| Flurbiprofen | 19 | $150 | $8 |
2013: 2 drugs
| Patanol | 25 | $3,421 | $137 |
| Flurbiprofen | 14 | $117 | $8 |
Money from drug and device companies
$117 in 2022
| 2022 | 1 | 1 | None | $117 |
| 2019 | 2 | 2 | None | $179 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| BioTissue Holdings | Prokera | $117 | 1 payment
|
See the published payment
| BioTissue Holdings | Meals · 2022-10-26 | Prokera | $117 |
See earlier years (2019)
2019: $179
| Amgen | Kyprolis | $125 | 1 payment
|
| Genentech USA | Lucentis | $54 | 1 payment
|
Professional record
- NPI
- 1881867455
- Licence
- CA 12124T
- Trained
- Southern California College of Optometry, 1998
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 152W00000X (152W00000X)
- Mailing address
- 751 S Bascom Ave, San Jose, CA, 95128
- NPI first listed
- 2008-04-03
- NPI last updated
- 2012-10-17
This is when the NPI record was last certified, not a medical board exam.